Medtronic (NYSE: MDT) has had its share of setbacks this year. But the medtech giant has also made moves that could set it up to significantly change how chronic health conditions such as atrial fibrillation are treated.
CEO Geoff Martha has insisted that the world’s largest medical device company can make good on its goals.
Here are the top Medtronic stories on MassDevice that got us to this point.
Despite the challenges during the company’s most recent quarter, Martha said the company has businesses where strategy and execution are yielding results.
The partnership centers around the needs and demand for care at ambulatory surgery centers (ASCs) and office-based labs (OBLs).
The three-year agreement is worth tens of millions of dollars.
“We are executing on our portfolio management strategy.”
The company said it submitted the final module of the Symplicity Spyral Premarket Approval package to the FDA for review and approval.
“We looked at the current state of robotics going back 10-plus years, and we realized there was an opportunity for us to come in.”
Medtronic’s renal care solutions business — which includes renal access, acute therapies and chronic therapies — will get rolled into the new company.
Affera started in 2014 with a simple goal that paid off when Medtronic bought the company this year. Achieving that goal, however, took some unconventional and sometimes difficult design choices.
The acquisition expanded the company’s cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed-field and radiofrequency ablation system.